Nektar Therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. Nektar also partners with the top biopharmaceutical companies to bring new products to market. To date, Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.

News Mar 8, 2010 Nektar Announces Positive Phase 2 Clinical Data from First Stage of NKTR-102 Study in Women with Platinum-Resistant Ovarian Cancer » Mar 2, 2010 Nektar Therapeutics' President and CEO Howard W. Robin to Present at the 30th Annual Cowen and Company Healthcare Conference in Boston » Mar 2, 2010 Nektar Therapeutics Reports Year-End 2009 Financial Results » Feb 23, 2010 Nektar to Announce Year-End 2009 Financial Results on Tuesday, March 2, 2010, After Close of U.S.-Based Financial Markets »

Contact Nektar investor relations Jennifer Ruddock Vice President of Investor Relations and Corporate Affairs 650-631-4954 Contact